LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Changes in Registrant’s Certifying Accountant

Item 4.01. Changes in Registrants Certifying Accountant.

(a)Dismissalof Independent Registered Public Accountant

OnMarch15, 2017, the Audit Committee (the Audit Committee)
of the Board of Directors of Loxo Oncology,Inc. (the
Company) approved
the dismissal ofCohnReznick LLP(CohnReznick) as
the Companys independent registered public accountant.

CohnReznicks reports on the Companys consolidated financial
statements for the fiscal years ended December31, 2016 and 2015
did not contain any adverse opinion or disclaimer of opinion, and
were not qualified or modified as to uncertainty, audit scope or
accounting principles.

During the fiscal years ended December31, 2016 and 2015, and
through March15, 2017, (i)there have been no disagreements (as
that term is used in Item 304(a)(1)(iv)of Regulation S-K and the
related instructions) between the Company and CohnReznick on any
matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which, if not
resolved to the satisfaction of CohnReznick would have caused
CohnReznick to make reference to the subject matter of the
disagreement in connection with its reports on the Companys
consolidated financial statements for such years, and (ii)there
were no reportable events (as that term is defined in Item
304(a)(1)(v)of Regulation S-K). The Company has given CohnReznick
permission to respond fully to the inquiries of the successor
auditor concerning this reportable event.

The Company has provided CohnReznick with a copy of this Form8-K
and requested that CohnReznick provide the Company with a letter
addressed to the Securities and Exchange Commission stating
whether or not CohnReznick agrees with the statements related to
them made by the Company in this report. A copy of CohnReznicks
letter, dated March21, 2017, is attached as Exhibit16.1 to this
report.

(b)Newly Appointed Independent Registered Public
Accountant

OnMarch15, 2017, the Audit Committee approved
theappointmentofErnst Young LLP (EY) as the
Companys new independent registered public accounting firm,
effective immediately, to perform independent audit services for
the fiscal year ending December31, 2017.

During the fiscal years ended December31, 2016 and 2015 and
through March15, 2017, neither the Company, nor anyone on its
behalf, consulted EY regarding either (i)the application of
accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be
rendered with respect to the consolidated financial statements of
the Company, in any case where a written report or oral advice
was provided to the Company by EY that EY concluded was an
important factor considered by the Company in reaching a decision
as to any accounting, auditing or financial reporting issue; or
(ii)any matter that was the subject of a disagreement (as that
term is used in Item 304(a)(1)(iv)of Regulation S-K and the
related instructions) or a reportable event (as that term is
defined in Item 304(a)(1)(v)of Regulation S-K).

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

About LOXO ONCOLOGY, INC. (NASDAQ:LOXO)

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.

LOXO ONCOLOGY, INC. (NASDAQ:LOXO) Recent Trading Information

LOXO ONCOLOGY, INC. (NASDAQ:LOXO) closed its last trading session 00.00 at 46.10 with 196,305 shares trading hands.